Form 4: Boston Scientific EVP Wendy Carruthers Executes Stock Options and Sells Shares Under 10b5-1 Plan

Wendy Carruthers, EVP of Human Resources at Boston Scientific, exercised stock options and sold shares of common stock on April 1, 2024, under a pre-established Rule 10b5-1 trading plan.

Summary

• On April 1, 2024, Wendy Carruthers, EVP of Human Resources at Boston Scientific, executed stock options to acquire 3,066 shares at $17.26 and 1,197 shares at $24.55.
• Simultaneously, Carruthers sold 6,983 shares of common stock at $68.42.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.
• Following these transactions, Carruthers directly owns 51,068 shares of Boston Scientific common stock and holds options for 47,287 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports transactions executed under a pre-existing plan. There's no indication of positive or negative implications for the company.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Executive stock option exercises and sales are common in publicly traded companies, especially in the healthcare sector. These transactions are often part of executive compensation packages and are subject to regulations to prevent insider trading.

Comparison to Industry Standards

• Executive compensation practices, including stock options, are common across the medical device industry.
• Companies like Medtronic (MDT) and Abbott Laboratories (ABT) also utilize stock options as part of their executive compensation packages.
• The use of Rule 10b5-1 trading plans is a standard practice to allow insiders to sell shares without raising concerns about insider trading.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are part of a pre-planned trading strategy.

Key Dates